Kefeng Wang

Dr. Kefeng Wang


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2016 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
XCXiaonan Chen
Xiaonan Chen
BWBin Wu
Bin Wu
ZXZhenqun Xu
Zhenqun Xu
SLShijie Li
Shijie Li
STShutao Tan
Shutao Tan
KWKefeng Wang
Kefeng Wang
We found microRNA‐133b (miR‐133b) was downregulated in urothelial carcinoma of the bladder (UCB) tissues, and it could inhibit the proliferation and induce apoptosis in UCB cells. Consequently, we intend to explore the clinical significance of miR‐133b in UCB patients. Expression of miR‐133b in 146 UCB specimens and matched adjacent non‐neoplastic bladder tissues were measured by quantitative real‐time polymerase chain reaction. The overall survival (OS) curve and progression‐free survival (PFS) curve were plotted using the Kaplan–Meier method. Prognostic factors for OS and PFS were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. The expression of miR‐133b was significantly downregulated in UCB tissues compared with those in adjacent non‐neoplastic bladder tissues (P < 0.001). Among UCB patients, low expression of miR‐133b significantly correlated with aggressive clinicopathological features. Multivariate analysis indicated that the expression of miR‐133b was the independent prognostic factors for predicting PFS (RR: 2.97; 95% CI: 1.78–6.44; P = 0.009) and OS (RR: 4.23; 95% CI: 1.51–11.8; P = 0.011) in patients with UCB. Our study demonstrated that downregulation of miR‐133b associated with aggressive clinicopathological features and predicted unfavorable prognosis in patients with UCB, might serve as feasible biomarker for clinical outcome of UCB patients after surgery and potential therapeutic target in the future.

11 January 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
XCXiaonan Chen
Xiaonan Chen
YZYiqiao Zhao
Yiqiao Zhao
ZTZijia Tao
Zijia Tao
KWKefeng Wang
Kefeng Wang
Objectives: To conduct a systematic review with meta-analysis of cohort studies to evaluate the association of coffee consumption with the risk of prostate cancer.Data sources: PubMed, Web of Science and Embase were searched for eligible studies up to September 2020.Study selection: Cohort studies were included.Data extraction and synthesis: Two researchers independently reviewed the studies and extracted the data. Data synthesis was performed via systematic review and meta-analysis of eligible cohort studies. Meta-analysis was performed with the “metan” and “glst” commands in Stata 14.0.Main outcomes and measures: Prostate cancer was the main outcome. It was classified as localised prostate cancer which included localised or non-aggressive cancers; advanced prostate cancer which included advanced or aggressive cancers; or fatal prostate cancer which included fatal/lethal cancers or prostate cancer-specific deaths.Results: Sixteen prospective cohort studies were finally included, with 57 732 cases of prostate cancer and 1 081 586 total cohort members. Higher coffee consumption was significantly associated with a lower risk of prostate cancer. Compared with the lowest category of coffee consumption, the pooled relative risk (RR) was 0.91 (95% CI 0.84 to 0.98), I2= 53.2%) for the highest category of coffee consumption. There was a significant linear trend for the association (p=0.006 for linear trend), with a pooled RR of 0.988 (95% CI 0.981 to 0.995) for each increment of one cup of coffee per day. For localised, advanced and fatal prostate cancer, the pooled RRs were 0.93 (95% CI 0.87 to 0.99), 0.88 (95% CI 0.71 to 1.09) and 0.84 (95% CI 0.66 to 1.08), respectively. No evidence of publication bias was indicated in this meta-analysis.Conclusions: This study suggests that a higher intake of coffee may be associated with a lower risk of prostate cancer.

17 August 2014 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Closed access
JHJun Huo
Jun Huo
ZLZhong-Yuan Liu
Zhong-Yuan Liu
KWKefeng Wang
Kefeng Wang
ZXzhenqun xu
zhenqun xu

28 February 2020 in Research Square
Verified
Preprint
Open access
PDF file
XCXiaonan Chen
Xiaonan Chen
YZYiqiao Zhao
Yiqiao Zhao
ZTZijia Tao
Zijia Tao
KWKefeng Wang
Kefeng Wang
Background Although in vitro and in vivo experiments have suggested that coffee may exert inhibitory effects on prostate carcinogenesis, epidemiological studies have reported inconsistent results on the association between coffee consumption and prostate cancer. Methods We conducted a meta-analysis of cohort studies to assess the association between coffee consumption and prostate cancer risk. PubMed and Embase were searched for eligible studies up to Jan 2020. Study-specific risk estimates were combined using fixed or random effects models depending on whether significant heterogeneity was detected. Results Fifteen prospective cohort studies, with 50,200 cases of prostate cancer and 949,752 total cohort members, were included in the meta-analysis. A statistically significant inverse association was detected between coffee consumption and prostate cancer risk. The pooled relative risk (RR) was 0.91 (95% CI: 0.84, 0.98; I 2= 53.2%) for the highest coffee consumption compared with lowest consumption. The association exhibited a linear trend ( P =0.006 for linear trend), and the pooled RR was 0.989 (95% CI: 0.982, 0.997) for an increase of 1 cup of coffee per day. The pooled RRs were 0.93 (95% CI: 0.87, 0.99), 0.88 (95% CI: 0.71, 1.09) and 0.84 (95% CI: 0.66, 1.08) for localized, advanced and fatal prostate cancer, respectively. No publication bias was detected. Conclusions Our findings provide more evidence that increased coffee consumption is associated with lower prostate cancer risk. It implies that men might be encouraged to increase the coffee intake to lower their risk of prostate cancer.

1 August 2008
Verified
Journal Article
Closed access
KWKefeng Wang
Kefeng Wang
BWBin Wu
Bin Wu

1 July 2007
Verified
Journal Article
Closed access
KWKefeng Wang
Kefeng Wang
BWBin Wu
Bin Wu
YZYang Zhang
Yang Zhang